Jun 2026 (Q2 FY26) — Aug 13, 2026
CapsoVision Q2 FY26 — Strong CapsoCam Plus Adoption and AI Highlights International Launch
Read the full callCapsoVision (CV) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
CapsoVision earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 3.6 | +9.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -208.1 | −67.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -7.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$6.45 −2.86% · −$0.19
Performance +37.5% 1Y
1Y: $4.69 on 14 Oct 2025 → $6.45. High $14.42 (11 Dec 2025), low $4.59 (4 Nov 2025).
- Previous close
- $6.64
- 52-week range
- $4.59 – $14.42
- One year
- +36.94%
Overview
- Symbol
- CV
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
CapsoVision earnings calls (CV)
Financials
What the filings say
Net profit, year on year: −62% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 3 | 3 | 3 | 4 | 4 | 3 | 4 |
| Operating profit | -6 | -5 | -5 | -5 | -8 | -7 | -7 | -8 |
| Operating margin | −195.7% | −134.2% | −193.4% | −140.3% | −226.7% | −190.5% | −254.1% | −208.1% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -6 | -5 | -5 | -5 | -8 | -7 | -7 | -7 |
| Tax rate | 0.0% | −0.2% | 0.0% | 0.0% | 0.0% | −0.3% | 0.0% | 0.0% |
| Net profit | -6 | -5 | -5 | -5 | -8 | -7 | -7 | -7 |
| EPS ($ per share) | -2.79 | — | -2.49 | -2.02 | -0.17 | — | -0.15 | -0.15 |
| Line item | Dec 2024 | Dec 2025 |
|---|---|---|
| Equity capital | 0 | 0 |
| Reserves | -130 | -156 |
| Total liabilities | 3 | 5 |
| Fixed assets | 1 | 1 |
| Total assets | 17 | 18 |
| Line item | Dec 2024 | Dec 2025 |
|---|---|---|
| Cash from operations | -20 | -23 |
| Cash from investing | -0 | -0 |
| Cash from financing | 15 | 24 |
| Capital expenditure | -0 | -0 |
| Free cash flow | -20 | -23 |
Insider filings
25 filings between Dec 31, 2025 and Sep 18, 2026.
Open market
decisions to buy or sellPurchases
$16.01M
6 purchases by 2 insiders
Sales
$8.6K
1 sale by 1 insider
Compensation
not trading decisions- 16
- Option exercise — converted options into shares
Also filed: 2 other filings.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| HARARI ELIYAHOU ET AL | $11.01M | — | Sep 18, 2026 |
| Shen Ching Hang | $5.00M | — | Sep 15, 2026 |
| Imperial Joanne Carol | — | $8.6K | Jun 8, 2026 |
Latest filings (33)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 18, 2026 | HARARI ELIYAHOU ET AL 10% owner | Purchase | 878,735 | $5.00M |
| Sep 18, 2026 | HARARI ELIYAHOU ET AL 10% owner | Purchase | 878,734 | $5.00M |
| Sep 15, 2026 | Shen Ching Hang 10% owner | Purchase | 878,734 | $5.00M |
| Jul 17, 2026 | HARARI ELIYAHOU ET AL 10% owner | Purchase | 61,068 | $411.0K |
| Jul 8, 2026 | HARARI ELIYAHOU ET AL 10% owner | Purchase | 81,300 | $495.1K |
| Jun 30, 2026 | Harari Michele Director | Option exercise | 2,022 | $15.3K |
| Jun 30, 2026 | King Wen-Herng Henry Director | Option exercise | 2,022 | $15.3K |
| Jun 30, 2026 | Tsai Chen Lung Director | Option exercise | 2,022 | $15.3K |
| Jun 30, 2026 | Imperial Joanne Carol Director | Option exercise | 2,022 | $15.3K |
| Jun 30, 2026 | GOUW JULIA S Director | Option exercise | 2,022 | $15.3K |
| Jun 30, 2026 | Kuo Hui Ying Director | Option exercise | 2,022 | $15.3K |
| Jun 26, 2026 | HARARI ELIYAHOU ET AL 10% owner | Purchase | 13,850 | $101.8K |
| Jun 8, 2026 | Imperial Joanne Carol Director | Sale | 1,200 | $8.6K |
| May 5, 2026 | Atkinson Douglas Patrick Head of Global Sales | Option exercise | 34,786 | $19.7K |
| May 4, 2026 | Atkinson Douglas Patrick Head of Global Sales | Option exercise | 6,505 | $3.7K |
| May 4, 2026 | Atkinson Douglas Patrick Head of Global Sales | Option exercise | 30,030 | $11.0K |
| May 4, 2026 | Atkinson Douglas Patrick Head of Global Sales | Option exercise | 36,036 | $10.3K |
| Apr 17, 2026 | Shen Ching Hang 10% owner | Other | 3,991,606 | $0 |
| Apr 17, 2026 | Shen Ching Hang 10% owner | Other | 3,991,606 | $0 |
| Dec 31, 2025 | Kuo Hui Ying Director | Option exercise | 2,887 | $30.9K |
| Dec 31, 2025 | Imperial Joanne Carol Director | Option exercise | 2,887 | $30.9K |
| Dec 31, 2025 | Harari Michele Director | Option exercise | 2,887 | $30.9K |
| Dec 31, 2025 | Tsai Chen Lung Director | Option exercise | 2,887 | $30.9K |
| Dec 31, 2025 | GOUW JULIA S Director | Option exercise | 2,887 | $30.9K |
| Dec 31, 2025 | King Wen-Herng Henry Director | Option exercise | 2,887 | $30.9K |
| Aug 18, 2025 | Petersen Rebecca Ann Director of Clinical Affairs | Option exercise | 24,834 | $9.1K |
| Jul 3, 2025 | Tsai Chen Lung Director | Purchase | 20 | $83 |
| Jul 3, 2025 | HARARI ELIYAHOU ET AL 10% owner | Conversion | 517,759 | — |
| Jul 3, 2025 | HARARI ELIYAHOU ET AL 10% owner | Conversion | 3,186,904 | — |
| Jul 3, 2025 | HARARI ELIYAHOU ET AL 10% owner | Conversion | 517,759 | — |
| Jul 3, 2025 | Wang Kang-Huai See Remarks | Conversion | 446,896 | — |
| Jul 3, 2025 | King Wen-Herng Henry Director | Conversion | 20,710 | — |
| Jul 3, 2025 | Kuo Hui Ying Director | Conversion | 10,354 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for CapsoVision, Inc
Free account. Everything above stays public.
Write why you follow CapsoVision, Inc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading